Tumourigenic Multidrug-Resistant HT1080 Cells and EGFR
Author Information
Author(s): M.L. Slovak, S.E.L. Mirski, S.P.C. Cole, J.H. Gerlach, K.H. Yohem, J.M. Trent
Primary Institution: City of Hope National Medical Center
Hypothesis
Does the lack of overexpression of epidermal growth factor receptors (EGFR) in HT1080/DR4 cells affect their tumorigenic potential?
Conclusion
HT1080/DR4 cells can form tumors in mice without overexpressing EGFR, indicating that drug resistance and tumorigenicity are independent events.
Supporting Evidence
- HT1080/DR4 cells do not overexpress P-glycoprotein.
- Both HT1080 and HT1080/DR4 cells formed tumors in mice.
- HT1080/DR4 tumors had a longer latency period and slower growth compared to HT1080 tumors.
Takeaway
The study found that a type of cancer cell that resists drugs can still grow tumors in mice, even though it doesn't have extra growth receptors.
Methodology
The study involved injecting HT1080 and HT1080/DR4 cells into mice to observe tumor formation and measuring tumor size and latency.
Limitations
The study only examined two specific cell lines and their behavior in a limited animal model.
Participant Demographics
Female BALB/c nude mice were used for the experiments.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website